These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17567634)

  • 1. Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden.
    Söderlin MK; Lindroth Y; Jacobsson LT
    Rheumatology (Oxford); 2007 Aug; 46(8):1355-8. PubMed ID: 17567634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A more active treatment has profound effects on the health status of rheumatoid arthritis (RA) patients: results from a population-based RA register in Malmö, Sweden, 1997-2005.
    Söderlin MK; Lindroth Y; Turesson C; Jacobsson LT
    Scand J Rheumatol; 2010 May; 39(3):206-11. PubMed ID: 20001765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response.
    Kosinski M; Kujawski SC; Martin R; Wanke LA; Buatti MC; Ware JE; Perfetto EM
    Am J Manag Care; 2002 Mar; 8(3):231-40. PubMed ID: 11915973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
    Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
    Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription rheumatology practices among Mexican specialists.
    Goycochea-Robles MV; Arce-Salinas CA; Guzmán-Vázquez S; Cardiel-Ríos MH
    Arch Med Res; 2007 Apr; 38(3):354-9. PubMed ID: 17350489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden.
    Gülfe A; Kristensen LE; Saxne T; Jacobsson LT; Petersson IF; Geborek P
    Ann Rheum Dis; 2010 Feb; 69(2):352-7. PubMed ID: 19282310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.
    van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Ewals JA; Han KH; Hazes JM; Kerstens PJ; Peeters AJ; van Zeben D; Breedveld FC; Huizinga TW; Dijkmans BA; Allaart CF
    Arthritis Rheum; 2009 Jan; 61(1):4-12. PubMed ID: 19116965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
    Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
    Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
    Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
    J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
    Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
    Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in longitudinal disease and treatment characteristics of patients with rheumatoid arthritis replying and not replying to a postal questionnaire. Experience from a biologics register in southern Sweden.
    Söderlin MK; Jacobsson LT; Petersson IF; Englund M; Saxne T; Geborek P
    J Rheumatol; 2009 Jun; 36(6):1166-9. PubMed ID: 19411397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outpatient follow-up for patients with rheumatoid arthritis in relation to New Zealand Rheumatology Association guidelines at Dunedin Hospital.
    Chan G; Goh F; Hodgson T; Hsu E; Johnstone D; Ly J; Platt T; Rodrigues E; Tsai W; Hider P; Gray A; Highton J
    N Z Med J; 2008 May; 121(1274):34-41. PubMed ID: 18535644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of a rheumatoid arthritis records-based index of severity.
    Ting G; Schneeweiss S; Katz JN; Weinblatt ME; Cabral D; Scranton RE; Solomon DH
    J Rheumatol; 2005 Sep; 32(9):1679-87. PubMed ID: 16142860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Agarwal S; Zaman T; Handa R
    Singapore Med J; 2009 Jul; 50(7):686-92. PubMed ID: 19644623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
    Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Ann Rheum Dis; 2005 Oct; 64(10):1421-6. PubMed ID: 15829572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy.
    Wolfe F; Michaud K
    J Rheumatol; 2007 Aug; 34(8):1674-83. PubMed ID: 17611989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
    Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
    J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden.
    Gülfe A; Kristensen LE; Saxne T; Jacobsson LT; Petersson IF; Geborek P
    Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1399-406. PubMed ID: 20506121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatoid arthritis is milder in the new millennium: health status in patients with rheumatoid arthritis 1994-2004.
    Uhlig T; Heiberg T; Mowinckel P; Kvien TK
    Ann Rheum Dis; 2008 Dec; 67(12):1710-5. PubMed ID: 18218667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responsiveness of health status measures and utility-based methods in patients with rheumatoid arthritis.
    Salaffi F; Stancati A; Carotti M
    Clin Rheumatol; 2002 Nov; 21(6):478-87. PubMed ID: 12447631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.